Research & Development
Zalgen to provide test kits for Lassa fever study in West Africa
Under the terms of the contract, Zalgen will supply its Lassa fever antibody testing kits (ReLASV Pan-Lassa NP IgG ELISA) to CEPI's Enable study partners in Benin, Guinea, Liberia, Nigeria, and Sierra Leone, to test up to 7,000 participants for Lassa fever antibodies, specifically the anti-Lassa virus nucleoprotein human immunoglobulin G (IgG) antibodies.
August 25, 2021
Universal COVID-19 testing advised for long-term care facilities
At the start of the COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention (CDC) recommended that only patients who exhibited symptoms consistent with COVID-19 (such as fever, cough, and other respiratory symptoms) should be tested for the disease. However, long-term care facilities have been a hot spot for SARS-CoV-2 infections, and mortality rates have remained high.
July 14, 2020
Pathologists advance understanding of deadly female genital tract infections
Group A strep is typically found in the mouth, but it can also infect other mucosal areas of the body, with deadly results. The researchers noted that GAS surface proteins cause an estimated 700 million human infections annually around the world, including 15 million in the U.S. GAS is at the root of puerperal sepsis (also known as childbed fever), which is the leading cause of maternal deaths, and it causes necrotizing myometritis (inflammation of the uterine myometrium) as well as severe infections in newborns.
March 18, 2020
Innovation in tests for spotted fever, TB | Guidance on breast cancer testing | What's next for PacBio and Illumina?
Dear LabPulse Member,
January 20, 2020
Point-of-care test for lethal spotted fever infections in the pipeline
The biomarker is the putative N-acetylmuramoyl-L-alanine amidase RC0497, a protein that was identified through an analysis of human umbilical vein endothelial cells infected with the bacterial pathogen Rickettsia conorrii. A blood test for the protein was successfully tested in a mouse model and in serum samples taken from infected humans, co-lead investigator Yingxin Zhao, PhD, a scientist at the Sealy Center for Molecular Medicine, University of Texas Medical Branch (UTMB), and colleagues reported.
January 20, 2020
Inflammatix scores BARDA contract for infection tests
Burlingame, CA-based Inflammatix developed the HostDx multiplex isothermal platform for mRNA testing at the point of care, with results available in less than 30 minutes. BARDA is part of the U.S. Department of Health and Human Services.
November 13, 2019
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
IGeneX reports data for tick-borne fever test
Tick-borne relapsing fever and Lyme disease (LD) are caused by two related Borrelia bacteria groups, each of which includes more than 20 species.
October 29, 2019
IGeneX survey flags gaps in tick-borne disease testing
The survey of 198 patients/customers tested between 2018 and 2019 highlights the challenges of getting a professional to make a diagnosis, as well as the financial impact of a delayed diagnosis, according to the company. IGeneX markets tests for Lyme disease, relapsing fever, babesiosis, and other conditions caused by ticks.
July 10, 2019
Page 1 of 1